CO4600683A1 - Bikunina humana - Google Patents

Bikunina humana

Info

Publication number
CO4600683A1
CO4600683A1 CO97013175A CO97013175A CO4600683A1 CO 4600683 A1 CO4600683 A1 CO 4600683A1 CO 97013175 A CO97013175 A CO 97013175A CO 97013175 A CO97013175 A CO 97013175A CO 4600683 A1 CO4600683 A1 CO 4600683A1
Authority
CO
Colombia
Prior art keywords
dsedhssdmf
clvskvvgrc
enpplplgsk
seq
adrersihdf
Prior art date
Application number
CO97013175A
Other languages
English (en)
Spanish (es)
Inventor
Paul P Tamburini
Gary Davis
Katherine A Delaria
Christopher W Marlor
Daniel K Muller
Original Assignee
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Corp filed Critical Bayer Corp
Publication of CO4600683A1 publication Critical patent/CO4600683A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • C07K14/8117—Bovine/basic pancreatic trypsin inhibitor (BPTI, aprotinin)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Wood Science & Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Plant Pathology (AREA)
CO97013175A 1996-03-11 1997-03-11 Bikunina humana CO4600683A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1310696P 1996-03-11 1996-03-11
US1979396P 1996-06-14 1996-06-14
US72525196A 1996-10-04 1996-10-04

Publications (1)

Publication Number Publication Date
CO4600683A1 true CO4600683A1 (es) 1998-05-08

Family

ID=27359773

Family Applications (1)

Application Number Title Priority Date Filing Date
CO97013175A CO4600683A1 (es) 1996-03-11 1997-03-11 Bikunina humana

Country Status (27)

Country Link
US (3) US6583108B1 (en:Method)
EP (1) EP0891426B1 (en:Method)
JP (2) JP3469584B2 (en:Method)
KR (1) KR100356956B1 (en:Method)
AR (3) AR006188A1 (en:Method)
AT (1) ATE328083T1 (en:Method)
AU (1) AU716923B2 (en:Method)
BR (1) BR9708021A (en:Method)
CA (1) CA2247888A1 (en:Method)
CO (1) CO4600683A1 (en:Method)
DE (1) DE69735996T2 (en:Method)
DK (1) DK0891426T3 (en:Method)
ES (1) ES2263174T3 (en:Method)
HR (1) HRP970144B1 (en:Method)
HU (1) HU226419B1 (en:Method)
ID (1) ID16224A (en:Method)
IL (1) IL126115A (en:Method)
IN (1) IN192874B (en:Method)
MY (1) MY120693A (en:Method)
NZ (1) NZ331540A (en:Method)
PA (1) PA8426301A1 (en:Method)
PL (1) PL188387B1 (en:Method)
PT (1) PT891426E (en:Method)
SV (1) SV1997000018A (en:Method)
TR (1) TR199801794T2 (en:Method)
WO (1) WO1997033996A2 (en:Method)
YU (1) YU8997A (en:Method)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
EP0758682B1 (en) * 1995-07-24 2004-05-12 Mitsubishi Chemical Corporation Hepatocyte growth factor activator inhibitor
ES2263174T3 (es) 1996-03-11 2006-12-01 Bayer Corporation Bikunina humana.
WO1998033920A2 (en) * 1997-01-31 1998-08-06 Human Genome Sciences, Inc. Tissue factor pathway inhibitor-3
JP3819239B2 (ja) * 1998-12-22 2006-09-06 バイエル アクチェンゲゼルシャフト 粘膜線毛クリアランスの速度を促進する方法
US6489308B1 (en) 1999-03-05 2002-12-03 Trustees Of University Of Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of nitric-oxide-induced clinical conditions
US7704958B1 (en) 1999-03-05 2010-04-27 Bio Holding, Inc. Methods and compositions for inhibiting apoptosis using serine protease inhibitors
US20040235715A1 (en) * 1999-11-12 2004-11-25 Bayer Corporation Method of producing glycosylated bikunin
IL140993A0 (en) 2000-05-15 2002-02-10 Bayer Ag Trypsin substrate and diagnostic device, and method of using same
IL140994A (en) * 2000-05-15 2005-12-18 Bayer Ag Urinary trypsin inhibitor assay containing a chelating agent
US6955921B2 (en) * 2001-04-30 2005-10-18 Bayer Corporation Trypsin substrate and diagnostic device, and method of using same
WO2003040330A2 (en) * 2001-11-05 2003-05-15 Curagen Corporation Therapeutic polypeptides, nucleic acids encoding same, and methods of use
PT2298278E (pt) 2002-06-07 2016-02-25 Dyax Corp Prevenção e redução da perda de sangue e resposta inflamatória
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
CN102775472A (zh) 2003-01-06 2012-11-14 安吉奥开米公司 作为穿过血脑屏障的载体的抑酶肽及类似物
US8460243B2 (en) 2003-06-10 2013-06-11 Abbott Diabetes Care Inc. Glucose measuring module and insulin pump combination
US7244616B2 (en) 2003-06-27 2007-07-17 Bayer Pharmaceuticals Corporation Use of molecular chaperones for the enhanced production of secreted, recombinant proteins in mammalian cells
US7722536B2 (en) 2003-07-15 2010-05-25 Abbott Diabetes Care Inc. Glucose measuring device integrated into a holster for a personal area network device
DK2520654T3 (en) 2003-08-26 2017-05-01 Univ Colorado Regents Inhibitors of serine protease activity and their use in methods and compositions for the treatment of bacterial infections
CA2541380A1 (en) * 2003-10-10 2005-04-21 Multicell Technologies, Inc. Use of cell lines to produce active therapeutic proteins
WO2005040222A1 (en) * 2003-10-16 2005-05-06 Bayer Healthcare Llc Monoclonal antibodies for detection of urinary trypsin inhibitors
EP1586587A1 (en) * 2004-04-16 2005-10-19 Exonhit Therapeutics SA Compositions and methods for detecting angiogenesis
US20060010098A1 (en) 2004-06-04 2006-01-12 Goodnow Timothy T Diabetes care host-client architecture and data management system
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
DK2360258T3 (en) * 2005-02-18 2015-01-12 Angiochem Inc Aprotininpolypeptider to transport a compound of blood-brain-barrier
US20090016959A1 (en) * 2005-02-18 2009-01-15 Richard Beliveau Delivery of antibodies to the central nervous system
WO2007011693A2 (en) * 2005-07-14 2007-01-25 Medistem Laboratories, Inc. Compositions of placentally-derived stem cells for the treatment of cancer
EP2471555A3 (en) 2005-07-15 2012-10-17 Angiochem Inc. Use of aprotinin polypeptides as carriers in pharmaceutical conjugates
US8093017B2 (en) 2005-12-07 2012-01-10 Siemens Heathcare Diagnostics Inc. Detection of soluble adiponectin receptor peptides and use in diagnostics and therapeutics
US8828703B2 (en) 2005-12-29 2014-09-09 Dyax Corp. Protease inhibition
EP2074138A4 (en) * 2006-09-19 2009-12-30 Phylogica Ltd NEUROPROTECTIVE PEPTIDE AP-1 SIGNALING INHIBITORS AND USES THEREOF
US20100063146A1 (en) * 2006-11-07 2010-03-11 Medof M Edward Method for treating disorders related to complement activation
WO2008077478A1 (en) * 2006-12-22 2008-07-03 Bayer Schering Pharma Aktiengesellschaft Preparation and use of variants of the kunitz domain 2 of the human placental bikunin gene
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
WO2008154700A1 (en) * 2007-06-20 2008-12-24 Phylogica Limited Compositions and uses thereof for the treatment of acute respiratory distress syndrome (ards) and clinical disorders associated with therewith
JP2010536870A (ja) * 2007-08-21 2010-12-02 ジェンザイム・コーポレーション カリクレイン阻害剤を用いた治療
DE102007056231A1 (de) 2007-09-08 2009-03-12 Bayer Healthcare Ag Herstellung und Verwendung von Varianten humander Kunitz-Typ Protease-Inhibitoren (hKTPI)
TR201905480T4 (tr) * 2008-04-18 2019-05-21 Angiochem Inc Paklitaksel, paklitaksel analogları veya paklitaksel konjugatlarının farmasötik bileşimleri ve ilgili preparasyon ve kullanım yöntemleri.
BRPI0920121A2 (pt) 2008-10-15 2019-09-24 Angiochem Inc conjugados de etoposida e doxorubicina para liberação de fármaco
EP2346906A4 (en) 2008-10-15 2013-04-24 Angiochem Inc CONJUGATES FROM GLP-1 AGONISTS AND THEIR USE
AU2009322043A1 (en) 2008-12-05 2011-07-07 Angiochem Inc. Conjugates of neurotensin or neurotensin analogs and uses thereof
JP2012512185A (ja) 2008-12-17 2012-05-31 アンジオケム インコーポレーテッド 膜１型マトリックス金属タンパク質阻害剤およびその使用
JP2013516389A (ja) 2009-01-06 2013-05-13 ダイアックス コーポレーション カリクレイン阻害剤による粘膜炎治療
MX2011011023A (es) 2009-04-20 2012-01-20 Angiochem Inc Tratamiento de cancer de ovarios usando un agente anti-cancer conjugado con un analogo de angiopep-2.
MX2012000016A (es) 2009-07-02 2012-03-26 Angiochem Inc Conjugados de peptidos multimericos y sus usos.
SI3459564T1 (sl) 2010-01-06 2022-06-30 Takeda Pharmaceutical Company Limited Proteini, ki vežejo plazemski kalikrein
EP2371857A1 (en) * 2010-04-01 2011-10-05 CSL Behring GmbH Factor XII inhibitors for treating interstitial lung disease
KR102320178B1 (ko) 2011-01-06 2021-11-02 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 결합 단백질
US10136845B2 (en) 2011-02-28 2018-11-27 Abbott Diabetes Care Inc. Devices, systems, and methods associated with analyte monitoring devices and devices incorporating the same
JP6216921B2 (ja) 2011-06-24 2017-11-01 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ アルファ−１抗トリプシン融合分子のための組成物、方法および使用
AU2013202648B2 (en) 2012-01-10 2016-05-19 Konkuk University Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
AU2013302270A1 (en) 2012-08-14 2015-03-26 Angiochem Inc. Peptide-dendrimer conjugates and uses thereof
EP3110434B1 (en) 2014-02-24 2018-09-19 Takeda GmbH Uti fusion proteins
AU2015235967B2 (en) 2014-03-27 2020-10-22 Takeda Pharmaceutical Company Limited Compositions and methods for treatment of diabetic macular edema
DK3307326T3 (da) 2015-06-15 2020-10-19 Angiochem Inc Fremgangsmåder til behandling af leptomeningeal karcinomatose
EP3387018A1 (en) 2015-12-11 2018-10-17 Dyax Corp. Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
WO2021178843A1 (en) 2020-03-05 2021-09-10 DiaMedica USA Inc. Ulinastatin polypeptides

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223482A (en) 1986-11-17 1993-06-29 Scios Nova Inc. Recombinant Alzheimer's protease inhibitory amyloid protein and method of use
US5106833A (en) 1987-07-23 1992-04-21 Washington University Coagulation inhibitors
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5663143A (en) 1988-09-02 1997-09-02 Dyax Corp. Engineered human-derived kunitz domains that inhibit human neutrophil elastase
DK0401508T3 (da) 1989-05-13 1995-05-15 Bayer Ag Proteaseinhibitorer, fremgangsmåde til deres fremstilling samt lægemidler med indhold deraf
DK408089D0 (da) 1989-08-18 1989-08-18 Novo Nordisk As Proteiner
ATE135044T1 (de) 1990-01-25 1996-03-15 Univ Washington Faktor x-laci-hybridprotein
DE69233108T2 (de) 1991-03-01 2004-04-29 Dyax Corp., Cambridge Hemmstoffe für menschliche neutrophile elastase und menschliches kathepsin g
RU2054180C1 (ru) 1991-08-21 1996-02-10 Жирнов Олег Петрович (н/п) Способ лечения вирусных респираторных инфекций
IL104326A0 (en) 1992-01-07 1993-05-13 Novo Nordisk As Variant of human kunitz-type protease inhibitor
IL104325A (en) 1992-01-07 2000-10-31 Novo Nordisk As Variants of human kunitz-type protease inhibitor domain II of tissue factor pathway inhibitor (TFPI) pharmaceutical compositions containing them a DNA construct encoding them their expression vectors a cell containing said DNA constructs and methods for the production of all the above
EP0651766A4 (en) 1992-07-13 1996-07-31 Corvas Int Inc INHIBITORS OF FACTOR Xa, DERIVED FROM THE INHIBITOR OF THE PANCREATIC TRYPSON FROM BEEF.
AU5684594A (en) 1992-12-02 1994-06-22 Novo Nordisk A/S Novel human amyloid protein precursor homologue and kunitz-type inhibitors
US5436153A (en) 1992-12-02 1995-07-25 Sprecher; Cindy A. Human amyloid protein precursor homolog and Kunitz-type inhibitor
JP2769083B2 (ja) 1993-02-22 1998-06-25 日清食品株式会社 エラスターゼ阻害活性を有する新規ペプチドおよびその製造方法
US5455338A (en) 1993-11-05 1995-10-03 Zymogenetics, Inc. DNA encoding novel human kunitz-type inhibitors and methods relating thereto
DK0739355T3 (da) 1994-01-11 2005-01-24 Dyax Corp Kallikrein-inhiberende "Kunitz-domæne"-proteiner og analoger deraf
JP4137997B2 (ja) 1994-01-11 2008-08-20 ダイアックス コープ． クニッツドメインから誘導されたヒトプラスミンの阻害剤
US5795954A (en) 1994-03-04 1998-08-18 Genentech, Inc. Factor VIIa inhibitors from Kunitz domain proteins
WO1996003503A1 (en) 1994-07-21 1996-02-08 The Green Cross Corporation Process for producing urinary trypsin inhibitor and domains thereof, novel polypeptide related to the both, and process for producing the polypeptide
US5541228A (en) * 1994-10-14 1996-07-30 Bristol-Myers Squibb Co. Melatonergic agents
JPH11504938A (ja) 1995-05-08 1999-05-11 サイオス インク． クニッツ型プロテアーゼ阻害因子
US5786328A (en) 1995-06-05 1998-07-28 Genentech, Inc. Use of kunitz type plasma kallikrein inhibitors
EP0758682B1 (en) * 1995-07-24 2004-05-12 Mitsubishi Chemical Corporation Hepatocyte growth factor activator inhibitor
US5736364A (en) 1995-12-04 1998-04-07 Genentech, Inc. Factor viia inhibitors
ES2263174T3 (es) 1996-03-11 2006-12-01 Bayer Corporation Bikunina humana.
WO1998033920A2 (en) 1997-01-31 1998-08-06 Human Genome Sciences, Inc. Tissue factor pathway inhibitor-3
US6294648B1 (en) * 1999-07-20 2001-09-25 Bayer Corporation Protein having proteinase inhibitor activity

Also Published As

Publication number Publication date
CA2247888A1 (en) 1997-09-18
AR006188A1 (es) 1999-08-11
HRP970144B1 (en) 2004-10-31
PT891426E (pt) 2006-10-31
PA8426301A1 (es) 2000-05-24
IL126115A0 (en) 1999-05-09
IN192874B (en:Method) 2004-05-29
HUP9902698A3 (en) 2001-06-28
AU2207797A (en) 1997-10-01
DK0891426T3 (da) 2006-10-02
NZ331540A (en) 1999-10-28
MY120693A (en) 2005-11-30
BR9708021A (pt) 1999-07-27
AR058982A1 (es) 2008-03-05
KR19990087697A (ko) 1999-12-27
WO1997033996A3 (en) 1997-11-13
EP0891426B1 (en) 2006-05-31
US6583108B1 (en) 2003-06-24
DE69735996D1 (de) 2006-07-06
AR053063A2 (es) 2007-04-18
US7452859B2 (en) 2008-11-18
DE69735996T2 (de) 2007-02-15
PL328822A1 (en) 1999-02-15
PL188387B1 (pl) 2005-01-31
JP2001521367A (ja) 2001-11-06
JP3469584B2 (ja) 2003-11-25
ES2263174T3 (es) 2006-12-01
US7019123B2 (en) 2006-03-28
AU716923B2 (en) 2000-03-09
HUP9902698A2 (hu) 1999-11-29
HU226419B1 (en) 2008-12-29
EP0891426A2 (en) 1999-01-20
YU8997A (sh) 1999-09-27
ID16224A (id) 1997-09-11
US20030194398A1 (en) 2003-10-16
TR199801794T2 (xx) 2000-07-21
IL126115A (en) 2007-03-08
US20060172946A1 (en) 2006-08-03
ATE328083T1 (de) 2006-06-15
KR100356956B1 (ko) 2003-03-15
SV1997000018A (es) 1999-01-14
WO1997033996A2 (en) 1997-09-18
HRP970144A2 (en) 1998-04-30
JP2004000208A (ja) 2004-01-08

Similar Documents

Publication Publication Date Title
CO4600683A1 (es) Bikunina humana
Boman et al. Chemical synthesis and enzymic processing of precursor forms of cecropins A and B
Fleer et al. The primary structure of bovine pancreatic phospholipase A2
Speicher et al. Erythrocyte spectrin is comprised of many homologous triple helical segments
ES2114539T3 (es) Expresion de polipeptidos recombinados con purificacion mejorada.
DE3485568D1 (de) Peptide aus alpha-aminoboronsaeuren.
EP0722461A4 (en) EXPRESSION OF FUSION POLYPEPTIDES TRANSPORTED OUT OF CYTOPLASM WITHOUT HEAD SEQUENCE
ES2073571T3 (es) Aplicacion de nuevos fragmentos de adn como secuencia que codifica un peptido señal para la secrecion de proteinas maduras, mediante levaduras recombinantes, cassettes de expresion, levaduras transformadas y procedimiento correspondiente de preparacion de proteinas.
AR036196A1 (es) Agentes de contraste multimericos dirigidos a base de peptidos
DK289688A (da) Ekspression af proapolipoprotein a-i.
ATE384787T1 (de) Tripeptidyl-aminopeptidase
ES2196088T3 (es) Analogos del factor de crecimiento de los queratinocitos.
AU5232886A (en) Serine protease inhibitors and methods for isolation of same
DE68917837D1 (de) Peptid-Verbindungen.
NO930428L (no) Proteinstrukturen til plantetoksingelonin
MX9701720A (es) Proceso para la fabricacion de una palidipina modificada, inhibidora de la agregacion plaquetaria inducida por colageno.
KR940009329A (ko) 딕티오스텔륨 디펩티딜아미노펩티다아제
FR2766190B1 (fr) Nouveaux peptides et polypeptides utiles dans la regeneration du systeme nerveux
ES2060134T3 (es) Inhibidor de tejido de metaloproteasas (timp-2).
PE20001068A1 (es) Produccion de analogos de tripsinogeno recombinante solubles
KR880701073A (ko) 제조합 dna 기법에 의해 생성된 민악티빈
DK0616642T3 (da) Hidtil ukendte thrombininhibitoriske proteiner fra landblodigler
ATE266094T1 (de) Produktion des proteins ingap mit hoher expressionsrate
PT975742E (pt) Aminopeptidase derivada de bacillus licheniformis e processo para a preparacao de proteinas do tipo natural
CO5210980A1 (es) PROTEINA V[sub E] Y SECUENCIAS DE ACIDO NUCLEICO, COMPOSICIONES, Y METODOS DE RESISTENCIA A PATOGENOS VEGETALES